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Summary
Background Biologic therapies have revolutionized the treatment of moderate-to-
severe psoriasis. However, for reasons largely unknown, many patients do not
respond or lose response to these drugs.
Objectives To evaluate demographic, social and clinical factors that could be
used to predict effectiveness and stratify response to biologic therapies in
psoriasis.
Methods Using a multicentre, observational, prospective pharmacovigilance study
(BADBIR), we identified biologic-naive patients starting biologics with outcome
data at 6 (n = 3079) and 12 (n = 3110) months. Associations between 31 puta-
tive predictors and outcomes were investigated in univariate and multivariable
regression analyses. Potential stratifiers of treatment response were investigated
with statistical interactions.
Results Eight factors associated with reduced odds of achieving ≥ 90% improve-
ment in Psoriasis Area and Severity Index (PASI 90) at 6 months were identified
(described as odds ratio and 95% confidence interval): demographic (female sex,
078, 066–093); social (unemployment, 067, 045–099); unemployment due
to ill health (062, 048–082); ex- and current smoking (081, 066–099 and
079, 063–099, respectively); clinical factors (high weight, 099, 099–099);
psoriasis of the palms and/or soles (075, 061–091); and presence of small pla-
ques only compared with small and large plaques (078, 062–096). White eth-
nicity (148, 112–197) and higher baseline PASI (104, 103–104) were
associated with increased odds of achieving PASI 90. The findings were largely
consistent at 12 months. There was little evidence for predictors of differential
treatment response.
Conclusions Psoriasis phenotype and potentially modifiable factors are associated
with poor outcomes with biologics, underscoring the need for lifestyle man-
agement. Effect sizes suggest that these factors alone cannot inform treatment
selection.
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What’s already known about this topic?
• Biologic therapy used in the treatment of moderate-to-severe psoriasis differs in its
effectiveness across patients.
• Previous research has indicated that patients with a higher body mass index, who
smoke or who have smoked, and with a lower baseline Psoriasis Area and Severity
Index (PASI) are less likely to have a good outcome with biologic therapy for the
treatment of moderate-to-severe psoriasis.
What does this study add?
• This large-scale study in a real-world setting confirms that weight, smoking status
and baseline PASI are associated with effectiveness of biologic therapy.
• There is evidence that non-white ethnicity, female sex, unemployment, psoriasis of
the palms and soles and the presence of small chronic plaques are associated with
poor outcomes with biologics.
• There is some evidence that men have a comparatively worse response to etaner-
cept, relative to adalimumab, than women. Otherwise, most factors do not appear
to be predictors of differential treatment response.
Psoriasis is a common chronic inflammatory skin condition,
which is recognized by the World Health Organization as a
serious noncommunicable disease that requires effective man-
agement.1 Moderate-to-severe psoriasis (approximately > 10%
body surface area involvement) is increasingly treated with
biologic therapies. Clinical trials indicate that biologics are
effective for many patients in the short term,2 but not all
patients respond and, importantly, registry data show that
≥ 15% of patients discontinue treatment per annum.3 In addi-
tion, biologics are expensive (in the U.K. generally
> £10 000 per annum), so nonresponse or loss of response is
costly.
Significant investment into investigation of genomic fac-
tors that might influence treatment outcomes has not yet
made a clinical impact, as exemplified by a recent large-
scale investigation in patients with rheumatoid arthritis,
which concluded that genetic variants alone would be
unable to predict response to anti-tumour necrosis factor
(TNF)-a therapies.4 Indeed, the factors linked to lack of
effectiveness of biologic drugs are varied, but on the whole
are poorly understood, aside from high bodyweight, which
has consistently been associated with worse outcomes for
most biologic therapies.5–9 This raises the possibility that
other, as yet unidentified, demographic, social or clinical
factors may be relevant in determining response. If this is
the case, these would not be costly to ascertain and could
be modifiable. Investigations assessing the role that these
factors may play in predicting treatment outcomes in psori-
asis have been neglected.
The British Association of Dermatologists Biologic Interven-
tions Register (BADBIR) is a U.K.- and Republic of Ireland-
based, multicentre, pharmacovigilance registry for adults with
psoriasis starting on biologic (and standard systemic) thera-
pies, which was initiated in September 2007.10 This longitudi-
nal cohort dataset includes detailed demographic, social and
clinical information on all participants and thus provides a
resource of sufficient size and detail to investigate comprehen-
sively the extent to which these factors predict treatment out-
comes. The specific aims of the current study were: (i) to
identify baseline demographic, social and clinical factors that
predict the effectiveness of adalimumab, etanercept and ustek-
inumab therapy; (ii) to provide clinically useful measures of
association between predictors and outcome; and (iii) to
investigate effect modification of factors by treatment type and
consequentially to identify factors that could be used to
inform treatment stratification.
Materials and methods
Study design, setting and participants
An observational cohort study was performed using data from
BADBIR.10 Patients with chronic plaque psoriasis enrolled in
BADBIR up to 1 February 2017 who initiated either
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adalimumab, etanercept or ustekinumab as a first-line biologic
formed the study population for this analysis. Infliximab was
not included, as the baseline severity criteria to start this drug
are different from those of other biologics and the cohort size
is considerably smaller, creating difficulties for interaction
analyses. Both a baseline Psoriasis Area Severity Index (PASI)
and follow-up PASI (at approximately 6 or 12 months) were
required for inclusion in the study. For the main analyses,
patients were included regardless of whether or not they were
still receiving the treatment at the time of the follow-up PASI,
as stopping therapy may be linked to poor response. Patients
who had withdrawn from therapy at the time of the outcome
measure were excluded in a sensitivity analysis (Tables S1 and
S2; see Supporting Information).
Outcome assessment
The primary outcome was a binary indicator of a reduction of
PASI by ≥ 90% (PASI 90) within 6 months following treat-
ment initiation. A 4–8-month window was chosen to approxi-
mate 6 months. If a patient had multiple PASIs within this
time frame, the lowest value was used. Baseline PASI was
defined as the nearest PASI up to and including 6 months
prior to the treatment start date.3,11 PASI 90 at 12 months
(defined as a 10–14-month window) was also investigated, as
were PASI 75 and the attainment of absolute PASI ≤ 15; the
latter was chosen to approximate PASI 90 without relying on
the baseline PASI.
Covariates
Demographic factors (age at biologic initiation, sex, ethnicity as
white or non-white), lifestyle and social factors [work status,
body mass index (BMI), weight, alcohol intake, smoking status
as never/ex/current], skin type, disease characteristics (baseline
PASI; disease duration; family history; flexural psoriasis; psoria-
sis involvement on the scalp, nails and palms and/or soles;
small/large chronic plaque; psoriatic arthritis), Fitzpatrick skin
type, comorbidities (hypertension, angina, heart attack, stroke,
latent tuberculosis, diabetes, depression, dyslipidaemia, nonskin
cancer) and cotherapy factors (previous use of conventional
drugs, baseline concomitant methotrexate or ciclosporin) were
assessed for associations with PASI outcomes. The variables were
chosen due to their availability in BADBIR.
Statistical analyses
Univariate analyses (t-tests for approximately normally dis-
tributed continuous variables, Mann–Whitney test for non-
normal continuous variables, v2-tests for binary or categorical
variables) were performed to identify baseline factors associ-
ated with PASI 90, PASI 75 and absolute PASI ≤ 15 within 6
months and 12 months following the initiation of treatment.
Logistic multivariable regression models were fitted to assess
variables collectively with P < 02 from the corresponding uni-
variate analysis. The inclusion of those with P > 02 was also
explored to see whether any of these had an association with the
outcome when adjusting for other covariates. Predictors with
P < 005 in the 6-month analysis of PASI 90 were also included
in the subsequent models for other outcomes. Any biologic
therapy received was included in each multivariable model to
ensure that associations between the covariates and the outcome
were independent of choice of therapy. Continuous variables
were included as such in the main analyses, but additional
models were fitted where they were categorized to aid interpre-
tation.
Calibration (goodness of fit) of each model was assessed by
calculating the model-predicted probability of the outcome for
each individual and assessing the percentage of people who
did observe the outcome in categories of the predicted proba-
bilities and by using the Hosmer–Lemeshow test.12 For exam-
ple, we would expect around 20% of people who had a
model-predicted probability of 02 to have observed the out-
come. Discrimination (predictive ability) of the model was
assessed by calculating the area under the receiver operating
curve.12
Risk differences and the corresponding number needed to
treat (NNT) were calculated for each variable included in the
multivariable analysis for PASI 90 at 6 months to give a more
interpretable indication of the effect sizes.13 Adjusted risk dif-
ferences were estimated from the output of the logistic model
by averaging over the effects of the other model covariates.14
The NNT is the reciprocal of the risk difference. Continuous
variables were dichotomized by the sample median for this
analysis due to requirements of the methodology.
Interactions between the specific biologic therapy and the
variables included in the multivariable regression for PASI 90
at 6 months were investigated to identify effect modification
of these variables by treatment type. Interaction was assessed
on the multiplicative scale via the ratio of odds ratios (ORs)
and on the additive scale via the difference in risk differences.
A comparison of absolute treatment effects (here, risk differ-
ences) is more appropriate for the investigation of differential
treatment response as it is not influenced by differences in
baseline risks of the outcome across the subgroups being com-
pared, unlike comparisons of relative treatment measures.15
Each interaction analysis was adjusted for all other variables
included in the PASI 90 6-month multivariate model.
Where present, missing data for potential predictor variables
were accounted for by multiple imputation, performed using
the Stata chained command with 20 imputed datasets based on
the full set of independent variables with complete data and the
dependent variable. Analyses were performed in Stata 14.16
Sensitivity analyses
The multivariable analyses for PASI 90 at 6 and 12 months
were repeated: (i) excluding patients who were no longer
receiving the prescribed first-line biologic at the time of the
6-month PASI; and (ii) incorporating sampling weights (de-
fined as the probability of being included in the sample) to
© 2018 The Authors. British Journal of Dermatology
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account for potential sampling bias due to the exclusion of
patients without the required PASIs.17
Results
Participants, exposure, baseline characteristics and
response rates
Data from 7516 patients with chronic plaque psoriasis
enrolled in BADBIR up to 1 February 2017 were available
(Fig. 1). Of these, 5885 biologic-naive patients started adali-
mumab (3422, 581%), etanercept (1377, 234%) or ustek-
inumab (1086, 185%). Furthermore, 3079 (523%) had a
PASI score at baseline and 6 months and 3110 (528%) had
a PASI at baseline and 12 months. The median number of
days between the baseline PASI and the treatment start date
was 27 days, and 90% of patients’ baseline PASI scores were
within the 90 days prior. Their baseline characteristics were
in line with those in previous reports.18 The level of miss-
ingness for most variables was < 10%, but it was high for
alcohol intake (around 36%) (Table S3; see Supporting Infor-
mation).
Of those starting adalimumab, etanercept and ustekinumab,
501%, 201% and 499%, respectively, achieved PASI 90 at 6
months, with comparable outcomes at 12 months (for PASI
75 and PASI ≤ 15 outcomes, see Table S4 in Supporting
Information).
Characterization of demographic, social and clinical
factors associated with response
The univariate analyses assessing the association between each
variable and the attainment of PASI 90 (Table S5; see Support-
ing Information) identified 16 variables with P < 02 that
were taken forward to the multivariable analysis. White eth-
nicity was also taken forward, as subsequent exploration indi-
cated that this had a significant association when other
covariates were adjusted for. BMI was excluded due to high
correlation with weight.
Of the demographic and social factors, female sex [OR
078, 95% confidence interval (CI) 066–093], unemploy-
ment in those seeking work (OR 067, 95% CI 045–099),
unemployment due to ill health (OR 062, 95% CI 048–
082) and both ex-smoking (OR 081, 95% CI 066–099)
and current smoking (OR 079, 95% CI 063–099) were
associated with reduced odds of achieving PASI 90 at 6
months following treatment initiation (Fig. 2 and Table S6;
see Supporting Information). White ethnicity (OR 148, 95%
CI 112–197) was associated with increased odds of achieving
PASI 90 at 6 months.
With respect to the clinical factors, higher weight (OR 099,
95% CI 099–099), psoriasis involving the palms and/or soles
(OR 075, 95% CI 061–091) and having only small chronic
plaques (compared with both small and large chronic plaques)
(OR 078, 95% CI 062–096) were associated with reduced
Fig 1. Flow diagram showing selection of patients for inclusion in the main analyses. This figure shows how patients in the British Association of
Dermatologists Biologic Interventions Register (BADBIR) were selected to contribute to the study. PASI, Psoriasis Area and Severity Index.
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odds of achieving PASI 90 at 6 months. A higher baseline PASI
was associated with increased odds of this outcome (OR 104,
95% CI 103–105). Furthermore, categorization of weight
showed that those weighing 70–90 kg, 90–110 kg and ≥ 110
kg had lower odds of achieving PASI 90 at 6 months than
those weighing < 70 kg (OR 068, 95% CI 054–087; OR
056, 95% CI 044–073 and OR 046, 95% CI 034–061,
respectively).
The model fit the data well (Hosmer–Lemeshow P-value
061) and had an area under the curve of 070 (95% CI 067–
071), demonstrating reasonably good predictive ability
(Table S7; see Supporting Information).
Findings for the multivariable analysis for predictors of PASI
90 at 12 months were consistent with those at 6 months
regarding sex, weight, ex-smoking and psoriasis of the palms
and/soles (Fig. S1 and Table S6; see Supporting Information),
but there was less evidence for an association with work sta-
tus, current smoking and plaque size. However, there was evi-
dence that nail psoriasis was associated with reduced odds of
achieving PASI 90 at 12 months (OR 085, 95% CI 073–
100) and that psoriatic arthritis was associated with increased
odds of this outcome (OR 122, 95% CI 101–147). The cali-
bration and discrimination assessment statistics were similar to
those at 6 months.
Risk differences and corresponding NNTs aid interpretation
regarding the clinical utility of the potential predictors in the
PASI 90 analysis (Table S8; see Supporting Information). For
example, patients who had a bodyweight > 90 kg were, in
absolute terms, around 76% less likely to achieve PASI 90 at
6 months than those with a weight < 90 kg, and current and
ex-smokers were estimated to be, respectively, 55% and 50%
less likely to achieve PASI 90 at 6 months than nonsmokers.
Fig 2. This figure presents the odds ratios and corresponding 95% confidence intervals (CIs) investigating the associations between baseline factors
and the attainment of ≥ 90% improvement in Psoriasis Area and Severity Index (PASI) at 6 months. Estimates were obtained from a multivariable
logistic regression analysis. Results for white ethnicity and skin type are estimated from a model excluding the other due to similarities in these
two variables. Skin type was included as a continuous variable, where a higher value represents darker skin.
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The first sensitivity analysis that excluded patients who had
withdrawn from therapy by the time of their 6- or 12-month
PASI evaluation (giving n = 2703 and n = 2370 at 6 and 12
months, respectively) gave similar results to the main analyses
(Tables S1 and S2; see Supporting Information). However, the
association between female sex and outcome at 12 months was
weaker, suggesting that the negative association in the main anal-
ysis was partly due to more women withdrawing from therapy
and subsequently not achieving a good PASI reduction. Incorpo-
rating sampling weights to account for potential sampling bias
from excluding patients without the required PASI scores also
gave similar results to the main analyses (Tables S1 and S2).
Results for the analyses exploring predictors of PASI 75 and
absolute PASI ≤ 15 are shown in Tables S9 and S10 (see Sup-
porting Information).
Predictors of differential treatment response
The majority of variables tested were not associated with dif-
ferential response to etanercept or ustekinumab compared
with adalimumab (Table S11; see Supporting Information).
However, there was a suggestion that the absolute effect of
etanercept compared with adalimumab was more negative in
men than in women (difference in risk differences 0079,
95% CI 0002–016). In other words, male patients had a
comparatively worse response to etanercept, relative to adali-
mumab, than female patients.
Discussion
In this large-scale, real-world dataset of patients with psoriasis
we have found evidence that female sex, non-white ethnicity,
smoking (current or ever), higher weight, unemployment and
psoriasis involving the palms and/or soles are associated with
a reduced likelihood of response to biologic therapy up to 1
year. We also provided clinically useful measures of the asso-
ciations between predictors and outcomes via risk differences
and NNTs. In addition, a key finding from this study is that,
while there are factors associated with a poorer or better
response to biologic therapy for chronic plaque psoriasis in
general, most factors do not appear to be predictors of treat-
ment stratification: they would not aid the selection of the
optimal biologic therapy for a patient out of the available
options.
To our knowledge, other studies have found neither female
sex nor non-white ethnicity to be negatively associated with
response to biologics in psoriasis.5 Female sex has previously
been shown to be associated with discontinuation of biologic
therapy in patients with psoriasis, but this was mainly attribu-
ted to adverse events.3
This study shows that people who have plaque psoriasis
affecting their palms and/or soles have a lower PASI response
at both 6 and 12 months. There are relatively few clinical data
on this subtype of psoriasis; of the drugs studied in this analy-
sis only adalimumab has been the subject of a formal, ran-
domized controlled trial. This showed that 31% of patients
with psoriasis of the hands or feet (which we assume to be
similar to psoriasis of the palms or soles) achieved a clear or
nearly clear response on a Physician’s Global Assessment scale,
compared with 3% on placebo.19 This response is considerably
lower than that seen for psoriasis overall, where responses of
> 60% achieving PASI 75 would be expected. It should be
noted that this study was not looking at overall response of
disease and focused solely on response of the hands and feet.
Effective treatments for psoriasis at these sites remain a prior-
ity area for research.
Our findings agree with others that the modifiable factors of
higher weight and current smoking are associated with a poorer
response to first-line biologic therapy.6,8 Other studies have
mainly analysed BMI, rather than weight, but we consider there
to be a significant correlation between the two. The association
was weaker for ex-smokers than for current smokers.
A higher baseline PASI was associated with an increased
likelihood of achieving both PASI 90 and PASI 75, but not
absolute PASI ≤ 15. This suggests that patients with higher
baseline PASI have on average a larger relative reduction in
PASI score than those with a lower baseline PASI score, but do
not achieve a lower absolute PASI score. This association may
arise because PASI 75 and PASI 90 are functions of baseline
PASI, and achieving these outcomes requires patients with a
lower baseline PASI to reach a lower follow-up PASI than
those with a higher baseline PASI.
Some findings are consistent with those in other disease areas.
Female sex has been found to be associated with a poor response
to anti-TNF therapies in rheumatoid arthritis (RA)20–22 and
ankylosing spondylitis.23 It is not clear why women have a
poorer response to these therapies, but one factor may be that,
in general, women taking a variety of therapies have a higher
rate of severe adverse events.24,25 Smoking has been found to be
associated with poor response to anti-TNF therapies in RA20,21
and infliximab in Crohn disease.26,27 Studies have found a nega-
tive association between BMI and response to anti-TNF therapies
in RA21,22 and ankylosing spondylitis.23
This study has a number of strengths: the prospective
cohort study design, the large sample size, fully industry-inde-
pendent data analysis, and the external validity of the results
due to the participation of multiple dermatology centres
(153) across the U.K. and the Republic of Ireland.
In terms of the methodology, performing multivariable
analyses in addition to univariate analyses allows a more confi-
dent interpretation regarding the independent association
between the predictors and the PASI outcomes. For example,
several comorbidities that were associated with the outcome
in the univariate analyses had attenuated associations when
other variables such as weight and smoking were accounted
for in the multivariable analyses. Another advantage of our
methodology is that we investigated differential response to
the separate biologic therapies. Most studies investigate only
predictors of a good outcome under treatment, but predictors
of differential response aid clinicians in choosing the best
therapy for each patient. We also produced clinically inter-
pretable effect sizes of the associations.
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A significant limitation of our study is that only about half of
the patients registered with BADBIR who initiated one of the bio-
logics investigated had PASI measurements at the times required
for this analysis, leading to a high number of excluded patients.
Assessing absolute PASI response overcomes the need for a base-
line PASI, but most patients were excluded due to having no fol-
low-up PASI (862% and 874% of those excluded at 6 and 12
months, respectively). However, we did not find a notable differ-
ence in the baseline characteristics of those with and without the
required PASIs, and performing inverse probability weighting to
account for unrepresentative missingness (Tables S1 and S2; see
Supporting Information) gave similar results to the main analysis.
The missingness of follow-up PASIs would be problematic if
those with a missing PASI had typically higher or lower PASI than
those with the required PASI scores. However, the overall levels
of attainment of PASI 90 and PASI 75 at 6 and 12 months were as
expected, suggesting that this may not be the case.
We recognize that, due to the wealth of information collected
in BADBIR, several statistical tests were performed, increasing
the risk of type I errors. We can have more confidence that the
findings in line with previous research (weight, smoking status,
baseline PASI, psoriasis of the palms and soles) are not spurious.
We would be interested to see whether the findings relating to
white ethnicity, work status, small chronic plaques and sex can
be replicated independently.
In conclusion, data from more than 3000 patients in BADBIR
indicate that high bodyweight, smoking status, psoriasis on the
palms and/or soles, female sex, non-white ethnicity and unem-
ployment are associated with poorer effectiveness of biologic
therapies up to 1 year following initiation. Some of these factors
are modifiable and confirm the important role that a dermatolo-
gist plays in educating patients about behaviour change and life-
style management in addition to targeted biologic therapy.
Counselling regarding smoking cessation and weight-loss pro-
grammes are an important part of general health management;
this study highlights how these factors detrimentally affect treat-
ment effectiveness.28,29 Furthermore, the study provides some
of the first real-world data to support the hypothesis that
patients with plaque disease of the palms and/or soles do not
achieve the same levels of overall response as those without
involvement. We found little evidence that the clinical variables
were associated with differential response to the separate bio-
logics, therefore it is unlikely we can produce a reliable tool to
select the optimal therapy based on these factors alone. It is pos-
sible that an integrated approach across omics and clinical data
will be needed.4
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